Share Price and Basic Stock Data
Last Updated: January 15, 2026, 3:13 am
| PEG Ratio | 0.14 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Lupin Ltd, a key player in the pharmaceuticals sector, reported a current share price of ₹2,196 and a market capitalization of ₹1,00,410 Cr. The company has demonstrated consistent revenue growth, with sales increasing from ₹4,146 Cr in September 2022 to ₹5,039 Cr in September 2023. This upward trajectory is expected to continue, as sales are projected to reach ₹5,600 Cr by June 2024. Over the fiscal years, Lupin’s annual sales figures rose from ₹16,405 Cr in FY 2022 to ₹20,011 Cr in FY 2024, and are set to achieve ₹22,708 Cr in FY 2025. This growth reflects a robust demand for its product portfolio, which spans generics, branded formulations, and biotechnology. The company’s strategic focus on both domestic and international markets has been instrumental in maintaining this growth, positioning it favorably against industry competitors.
Profitability and Efficiency Metrics
Lupin Ltd reported a net profit of ₹4,348 Cr for the trailing twelve months, translating to a P/E ratio of 23.2, which is competitive within the pharmaceutical sector. The operating profit margin (OPM) rose significantly from 11% in September 2022 to 33% by September 2025, indicating strong cost management and improved operational efficiency. The return on equity (ROE) stood at 20.6%, while return on capital employed (ROCE) was reported at 21.3%, both of which are above typical industry averages. The company has also maintained a healthy interest coverage ratio (ICR) of 18.58x, suggesting that it can easily meet its interest obligations. However, the cash conversion cycle (CCC) increased to 223 days, which may indicate potential liquidity challenges if not managed effectively. Overall, these metrics underscore Lupin’s ability to generate profits while managing operational costs effectively.
Balance Sheet Strength and Financial Ratios
Lupin’s balance sheet reflects a solid financial position, with total borrowings reported at ₹6,217 Cr against reserves of ₹19,541 Cr, indicating a debt-to-equity ratio of 0.29. This suggests prudent leverage, allowing the company to finance growth without over-reliance on debt. The current ratio stood at 1.87, indicating sufficient liquidity to cover short-term liabilities. Furthermore, the company’s book value per share increased to ₹376.77 in FY 2025 from ₹275.67 in FY 2023, reflecting a strengthening net asset position. The company’s price-to-book value (P/BV) ratio of 5.38x suggests that it is trading at a premium relative to its book value, often indicative of strong market confidence. However, rising interest payments, which were ₹92 Cr in June 2025, could pose challenges if not balanced with revenue growth. Overall, Lupin’s balance sheet strength supports its operational and strategic initiatives.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Lupin Ltd indicates a diversified ownership structure, with promoters holding 46.89%, foreign institutional investors (FIIs) at 20.50%, domestic institutional investors (DIIs) at 26.56%, and the public at 6.06%. The gradual decline in promoter holding from 47.10% in December 2022 to the current level may raise questions about long-term commitment, but the stable presence of FIIs and DIIs reflects strong institutional confidence in the company’s prospects. The number of shareholders decreased from 3,60,677 in December 2022 to 2,80,256 in September 2025, suggesting potential consolidation among investors. The company’s commitment to shareholder returns is evident in its dividend payout ratio, which stood at 11.11% for FY 2025. This ratio indicates a balanced approach to rewarding shareholders while retaining sufficient earnings for reinvestment in growth initiatives.
Outlook, Risks, and Final Insight
Lupin Ltd’s outlook remains positive, bolstered by strong revenue growth, improved profitability, and a solid balance sheet. However, risks persist, including the potential for increased competition in the pharmaceuticals sector and fluctuations in raw material costs, which could impact margins. Additionally, the rising cash conversion cycle may strain liquidity if not addressed. The company is well-positioned to leverage its product pipeline and expanding market presence to drive future growth. If the company can manage its operational efficiency and maintain its competitive edge, it may continue to deliver strong financial performance. Conversely, failure to address rising costs or competition could hinder its growth trajectory. Overall, Lupin’s strategic initiatives, coupled with its financial health, provide a stable foundation for navigating the evolving pharmaceutical landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 136 Cr. | 108 | 207/84.3 | 30.1 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,079 Cr. | 374 | 479/192 | 84.5 | 24.3 | 0.18 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.3 Cr. | 44.8 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.4 Cr. | 39.9 | 41.0/17.0 | 139 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,146.18 Cr | 1,124.06 | 52.86 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,146 | 4,322 | 4,430 | 4,814 | 5,039 | 5,197 | 4,961 | 5,600 | 5,673 | 5,768 | 5,667 | 6,268 | 7,048 |
| Expenses | 3,693 | 3,790 | 3,852 | 3,958 | 4,121 | 4,159 | 3,964 | 4,359 | 4,332 | 4,412 | 4,346 | 4,541 | 4,706 |
| Operating Profit | 453 | 533 | 578 | 856 | 918 | 1,038 | 997 | 1,241 | 1,340 | 1,356 | 1,321 | 1,727 | 2,341 |
| OPM % | 11% | 12% | 13% | 18% | 18% | 20% | 20% | 22% | 24% | 24% | 23% | 28% | 33% |
| Other Income | 15 | 18 | 37 | 23 | 40 | 29 | 29 | 68 | 42 | 54 | 57 | 79 | 90 |
| Interest | 55 | 84 | 93 | 86 | 81 | 74 | 71 | 68 | 71 | 67 | 89 | 92 | 108 |
| Depreciation | 203 | 220 | 264 | 235 | 248 | 257 | 457 | 248 | 257 | 271 | 393 | 299 | 317 |
| Profit before tax | 210 | 246 | 258 | 559 | 630 | 736 | 498 | 993 | 1,055 | 1,071 | 896 | 1,416 | 2,007 |
| Tax % | 36% | 36% | 6% | 19% | 21% | 16% | 26% | 19% | 19% | 20% | 13% | 14% | 26% |
| Net Profit | 134 | 158 | 242 | 453 | 495 | 619 | 368 | 806 | 859 | 859 | 782 | 1,221 | 1,485 |
| EPS in Rs | 2.85 | 3.37 | 5.19 | 9.94 | 10.76 | 13.47 | 7.89 | 17.58 | 18.69 | 18.74 | 16.92 | 26.69 | 32.36 |
Last Updated: January 11, 2026, 2:17 pm
Below is a detailed analysis of the quarterly data for Lupin Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 7,048.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,268.00 Cr. (Jun 2025) to 7,048.00 Cr., marking an increase of 780.00 Cr..
- For Expenses, as of Sep 2025, the value is 4,706.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,541.00 Cr. (Jun 2025) to 4,706.00 Cr., marking an increase of 165.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 2,341.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,727.00 Cr. (Jun 2025) to 2,341.00 Cr., marking an increase of 614.00 Cr..
- For OPM %, as of Sep 2025, the value is 33.00%. The value appears strong and on an upward trend. It has increased from 28.00% (Jun 2025) to 33.00%, marking an increase of 5.00%.
- For Other Income, as of Sep 2025, the value is 90.00 Cr.. The value appears strong and on an upward trend. It has increased from 79.00 Cr. (Jun 2025) to 90.00 Cr., marking an increase of 11.00 Cr..
- For Interest, as of Sep 2025, the value is 108.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 92.00 Cr. (Jun 2025) to 108.00 Cr., marking an increase of 16.00 Cr..
- For Depreciation, as of Sep 2025, the value is 317.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 299.00 Cr. (Jun 2025) to 317.00 Cr., marking an increase of 18.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 2,007.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,416.00 Cr. (Jun 2025) to 2,007.00 Cr., marking an increase of 591.00 Cr..
- For Tax %, as of Sep 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 14.00% (Jun 2025) to 26.00%, marking an increase of 12.00%.
- For Net Profit, as of Sep 2025, the value is 1,485.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,221.00 Cr. (Jun 2025) to 1,485.00 Cr., marking an increase of 264.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 32.36. The value appears strong and on an upward trend. It has increased from 26.69 (Jun 2025) to 32.36, marking an increase of 5.67.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:02 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 11,286 | 12,770 | 14,256 | 17,367 | 15,797 | 14,665 | 15,375 | 15,163 | 16,405 | 16,642 | 20,011 | 22,708 | 24,751 |
| Expenses | 8,271 | 9,146 | 10,564 | 12,865 | 12,649 | 12,104 | 13,020 | 12,596 | 16,187 | 14,921 | 16,211 | 17,430 | 18,005 |
| Operating Profit | 3,015 | 3,624 | 3,691 | 4,502 | 3,148 | 2,561 | 2,355 | 2,567 | 219 | 1,721 | 3,800 | 5,278 | 6,746 |
| OPM % | 27% | 28% | 26% | 26% | 20% | 17% | 15% | 17% | 1% | 10% | 19% | 23% | 27% |
| Other Income | 105 | 235 | 184 | 106 | -1,310 | 91 | -134 | 138 | 210 | 151 | 131 | 202 | 280 |
| Interest | 27 | 10 | 59 | 153 | 204 | 302 | 363 | 141 | 143 | 274 | 312 | 295 | 355 |
| Depreciation | 261 | 435 | 487 | 912 | 1,086 | 846 | 970 | 887 | 1,659 | 881 | 1,197 | 1,169 | 1,280 |
| Profit before tax | 2,832 | 3,415 | 3,329 | 3,543 | 547 | 1,503 | 887 | 1,676 | -1,372 | 716 | 2,422 | 4,015 | 5,390 |
| Tax % | 34% | 28% | 32% | 28% | 53% | 59% | 130% | 27% | 10% | 38% | 20% | 18% | |
| Net Profit | 1,870 | 2,444 | 2,270 | 2,565 | 258 | 615 | -270 | 1,228 | -1,528 | 448 | 1,936 | 3,306 | 4,348 |
| EPS in Rs | 40.96 | 53.47 | 50.17 | 56.63 | 5.56 | 13.40 | -5.95 | 26.81 | -33.62 | 9.45 | 42.01 | 71.88 | 94.71 |
| Dividend Payout % | 15% | 14% | 15% | 13% | 90% | 37% | -101% | 24% | -12% | 42% | 19% | 17% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 30.70% | -7.12% | 13.00% | -89.94% | 138.37% | -143.90% | 554.81% | -224.43% | 129.32% | 332.14% | 70.76% |
| Change in YoY Net Profit Growth (%) | 0.00% | -37.81% | 20.12% | -102.94% | 228.31% | -282.27% | 698.72% | -779.24% | 353.75% | 202.82% | -261.38% |
Lupin Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 8% |
| 3 Years: | 11% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 55% |
| 3 Years: | 60% |
| TTM: | 63% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 15% |
| 3 Years: | 44% |
| 1 Year: | -15% |
| Return on Equity | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 8% |
| 3 Years: | 13% |
| Last Year: | 21% |
Last Updated: September 5, 2025, 9:55 am
Balance Sheet
Last Updated: December 4, 2025, 1:35 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 90 | 90 | 90 | 90 | 90 | 90 | 91 | 91 | 91 | 91 | 91 | 91 | 91 |
| Reserves | 6,842 | 8,784 | 11,073 | 13,407 | 13,487 | 13,652 | 12,446 | 13,712 | 12,062 | 12,374 | 14,199 | 17,112 | 19,541 |
| Borrowings | 654 | 537 | 7,178 | 7,966 | 7,143 | 8,496 | 6,305 | 5,129 | 4,158 | 4,542 | 2,922 | 5,448 | 6,217 |
| Other Liabilities | 2,550 | 3,642 | 3,957 | 4,749 | 5,300 | 5,423 | 5,968 | 4,498 | 5,340 | 5,794 | 6,539 | 6,327 | 7,651 |
| Total Liabilities | 10,135 | 13,054 | 22,298 | 26,212 | 26,020 | 27,661 | 24,810 | 23,430 | 21,651 | 22,800 | 23,751 | 28,978 | 33,500 |
| Fixed Assets | 3,356 | 4,368 | 8,717 | 11,033 | 10,362 | 11,087 | 7,938 | 7,881 | 7,382 | 8,355 | 8,878 | 9,719 | 10,252 |
| CWIP | 304 | 576 | 2,702 | 2,133 | 2,598 | 1,640 | 940 | 1,066 | 1,146 | 1,238 | 773 | 517 | 593 |
| Investments | 178 | 1,658 | 16 | 2,136 | 262 | 2,295 | 2,374 | 2,455 | 900 | 517 | 1,075 | 1,146 | 3,331 |
| Other Assets | 6,297 | 6,451 | 10,862 | 10,910 | 12,798 | 12,639 | 13,557 | 12,028 | 12,224 | 12,690 | 13,026 | 17,596 | 19,325 |
| Total Assets | 10,135 | 13,054 | 22,298 | 26,212 | 26,020 | 27,661 | 24,810 | 23,430 | 21,651 | 22,800 | 23,751 | 28,978 | 33,500 |
Below is a detailed analysis of the balance sheet data for Lupin Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 91.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 91.00 Cr..
- For Reserves, as of Sep 2025, the value is 19,541.00 Cr.. The value appears strong and on an upward trend. It has increased from 17,112.00 Cr. (Mar 2025) to 19,541.00 Cr., marking an increase of 2,429.00 Cr..
- For Borrowings, as of Sep 2025, the value is 6,217.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 5,448.00 Cr. (Mar 2025) to 6,217.00 Cr., marking an increase of 769.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 7,651.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,327.00 Cr. (Mar 2025) to 7,651.00 Cr., marking an increase of 1,324.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 33,500.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 28,978.00 Cr. (Mar 2025) to 33,500.00 Cr., marking an increase of 4,522.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 10,252.00 Cr.. The value appears strong and on an upward trend. It has increased from 9,719.00 Cr. (Mar 2025) to 10,252.00 Cr., marking an increase of 533.00 Cr..
- For CWIP, as of Sep 2025, the value is 593.00 Cr.. The value appears strong and on an upward trend. It has increased from 517.00 Cr. (Mar 2025) to 593.00 Cr., marking an increase of 76.00 Cr..
- For Investments, as of Sep 2025, the value is 3,331.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,146.00 Cr. (Mar 2025) to 3,331.00 Cr., marking an increase of 2,185.00 Cr..
- For Other Assets, as of Sep 2025, the value is 19,325.00 Cr.. The value appears strong and on an upward trend. It has increased from 17,596.00 Cr. (Mar 2025) to 19,325.00 Cr., marking an increase of 1,729.00 Cr..
- For Total Assets, as of Sep 2025, the value is 33,500.00 Cr.. The value appears strong and on an upward trend. It has increased from 28,978.00 Cr. (Mar 2025) to 33,500.00 Cr., marking an increase of 4,522.00 Cr..
Notably, the Reserves (19,541.00 Cr.) exceed the Borrowings (6,217.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -651.00 | -534.00 | -4.00 | -3.00 | -4.00 | -6.00 | -4.00 | -3.00 | 215.00 | -3.00 | 1.00 | 0.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 80 | 76 | 116 | 91 | 120 | 128 | 129 | 108 | 95 | 98 | 86 | 88 |
| Inventory Days | 204 | 220 | 276 | 266 | 253 | 283 | 232 | 279 | 261 | 242 | 272 | 292 |
| Days Payable | 152 | 172 | 168 | 189 | 178 | 184 | 162 | 137 | 129 | 136 | 163 | 158 |
| Cash Conversion Cycle | 131 | 124 | 225 | 167 | 195 | 227 | 199 | 249 | 227 | 204 | 195 | 223 |
| Working Capital Days | 81 | 56 | 102 | 63 | 126 | 115 | 33 | 34 | 45 | 32 | 53 | 58 |
| ROCE % | 41% | 40% | 24% | 19% | 10% | 10% | 9% | 9% | -7% | 6% | 16% | 21% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Balanced Advantage Fund | 5,705,582 | 1.1 | 1188.02 | N/A | N/A | N/A |
| HDFC Large Cap Fund | 4,615,980 | 2.37 | 961.14 | N/A | N/A | N/A |
| Mirae Asset Large & Midcap Fund | 4,285,561 | 2.05 | 892.34 | N/A | N/A | N/A |
| HDFC Flexi Cap Fund | 4,200,000 | 0.93 | 874.52 | N/A | N/A | N/A |
| Nippon India Pharma Fund | 3,083,991 | 7.59 | 642.15 | N/A | N/A | N/A |
| Mirae Asset Midcap Fund | 2,835,782 | 3.21 | 590.47 | 2,735,782 | 2025-12-15 08:40:45 | 3.66% |
| ICICI Prudential Value Fund | 2,823,402 | 0.97 | 587.89 | N/A | N/A | N/A |
| SBI ELSS Tax Saver Fund | 2,687,887 | 1.73 | 559.67 | N/A | N/A | N/A |
| Nippon India Growth Mid Cap Fund | 2,552,382 | 1.26 | 531.46 | N/A | N/A | N/A |
| Nippon India Multi Cap Fund | 2,520,027 | 1.05 | 524.72 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 71.95 | 42.05 | 9.46 | -33.65 | 26.84 |
| Diluted EPS (Rs.) | 71.95 | 41.87 | 9.41 | -33.65 | 26.72 |
| Cash EPS (Rs.) | 98.02 | 68.74 | 29.20 | 3.28 | 46.59 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 376.77 | 315.41 | 275.67 | 268.91 | 305.45 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 376.77 | 315.41 | 275.67 | 268.91 | 305.45 |
| Revenue From Operations / Share (Rs.) | 497.33 | 439.12 | 365.75 | 360.96 | 334.21 |
| PBDIT / Share (Rs.) | 120.00 | 86.26 | 41.13 | 9.44 | 59.58 |
| PBIT / Share (Rs.) | 94.39 | 59.99 | 21.78 | -27.06 | 40.02 |
| PBT / Share (Rs.) | 87.93 | 53.15 | 15.75 | -30.20 | 36.92 |
| Net Profit / Share (Rs.) | 72.41 | 42.47 | 9.84 | -33.22 | 27.04 |
| NP After MI And SOA / Share (Rs.) | 71.87 | 42.01 | 9.45 | -33.62 | 26.81 |
| PBDIT Margin (%) | 24.12 | 19.64 | 11.24 | 2.61 | 17.82 |
| PBIT Margin (%) | 18.97 | 13.66 | 5.95 | -7.49 | 11.97 |
| PBT Margin (%) | 17.68 | 12.10 | 4.30 | -8.36 | 11.04 |
| Net Profit Margin (%) | 14.55 | 9.67 | 2.69 | -9.20 | 8.08 |
| NP After MI And SOA Margin (%) | 14.45 | 9.56 | 2.58 | -9.31 | 8.02 |
| Return on Networth / Equity (%) | 19.07 | 13.39 | 3.45 | -12.57 | 8.81 |
| Return on Capital Employeed (%) | 21.29 | 17.64 | 7.23 | -9.07 | 11.96 |
| Return On Assets (%) | 11.23 | 7.97 | 1.87 | -7.00 | 5.15 |
| Long Term Debt / Equity (X) | 0.10 | 0.00 | 0.00 | 0.01 | 0.00 |
| Total Debt / Equity (X) | 0.29 | 0.18 | 0.34 | 0.31 | 0.22 |
| Asset Turnover Ratio (%) | 0.85 | 0.85 | 0.50 | 0.51 | 0.47 |
| Current Ratio (X) | 1.87 | 1.58 | 1.34 | 1.51 | 1.66 |
| Quick Ratio (X) | 1.26 | 0.99 | 0.85 | 0.94 | 1.17 |
| Inventory Turnover Ratio (X) | 4.35 | 0.87 | 0.82 | 0.77 | 0.88 |
| Dividend Payout Ratio (NP) (%) | 11.11 | 9.50 | 42.28 | -19.31 | 22.34 |
| Dividend Payout Ratio (CP) (%) | 8.19 | 5.85 | 13.87 | 225.82 | 12.92 |
| Earning Retention Ratio (%) | 88.89 | 90.50 | 57.72 | 119.31 | 77.66 |
| Cash Earning Retention Ratio (%) | 91.81 | 94.15 | 86.13 | -125.82 | 87.08 |
| Interest Coverage Ratio (X) | 18.58 | 12.61 | 6.82 | 3.00 | 19.22 |
| Interest Coverage Ratio (Post Tax) (X) | 12.21 | 7.21 | 2.63 | -9.57 | 9.72 |
| Enterprise Value (Cr.) | 94555.16 | 75275.95 | 32506.42 | 36722.71 | 47698.57 |
| EV / Net Operating Revenue (X) | 4.16 | 3.76 | 1.95 | 2.24 | 3.15 |
| EV / EBITDA (X) | 17.26 | 19.15 | 17.37 | 85.62 | 17.65 |
| MarketCap / Net Operating Revenue (X) | 4.07 | 3.68 | 1.77 | 2.07 | 3.05 |
| Retention Ratios (%) | 88.88 | 90.49 | 57.71 | 119.31 | 77.65 |
| Price / BV (X) | 5.38 | 5.16 | 2.36 | 2.79 | 3.36 |
| Price / Net Operating Revenue (X) | 4.07 | 3.68 | 1.77 | 2.07 | 3.05 |
| EarningsYield | 0.03 | 0.02 | 0.01 | -0.04 | 0.02 |
After reviewing the key financial ratios for Lupin Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 71.95. This value is within the healthy range. It has increased from 42.05 (Mar 24) to 71.95, marking an increase of 29.90.
- For Diluted EPS (Rs.), as of Mar 25, the value is 71.95. This value is within the healthy range. It has increased from 41.87 (Mar 24) to 71.95, marking an increase of 30.08.
- For Cash EPS (Rs.), as of Mar 25, the value is 98.02. This value is within the healthy range. It has increased from 68.74 (Mar 24) to 98.02, marking an increase of 29.28.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 376.77. It has increased from 315.41 (Mar 24) to 376.77, marking an increase of 61.36.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 376.77. It has increased from 315.41 (Mar 24) to 376.77, marking an increase of 61.36.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 497.33. It has increased from 439.12 (Mar 24) to 497.33, marking an increase of 58.21.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 120.00. This value is within the healthy range. It has increased from 86.26 (Mar 24) to 120.00, marking an increase of 33.74.
- For PBIT / Share (Rs.), as of Mar 25, the value is 94.39. This value is within the healthy range. It has increased from 59.99 (Mar 24) to 94.39, marking an increase of 34.40.
- For PBT / Share (Rs.), as of Mar 25, the value is 87.93. This value is within the healthy range. It has increased from 53.15 (Mar 24) to 87.93, marking an increase of 34.78.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 72.41. This value is within the healthy range. It has increased from 42.47 (Mar 24) to 72.41, marking an increase of 29.94.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 71.87. This value is within the healthy range. It has increased from 42.01 (Mar 24) to 71.87, marking an increase of 29.86.
- For PBDIT Margin (%), as of Mar 25, the value is 24.12. This value is within the healthy range. It has increased from 19.64 (Mar 24) to 24.12, marking an increase of 4.48.
- For PBIT Margin (%), as of Mar 25, the value is 18.97. This value is within the healthy range. It has increased from 13.66 (Mar 24) to 18.97, marking an increase of 5.31.
- For PBT Margin (%), as of Mar 25, the value is 17.68. This value is within the healthy range. It has increased from 12.10 (Mar 24) to 17.68, marking an increase of 5.58.
- For Net Profit Margin (%), as of Mar 25, the value is 14.55. This value exceeds the healthy maximum of 10. It has increased from 9.67 (Mar 24) to 14.55, marking an increase of 4.88.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 14.45. This value is within the healthy range. It has increased from 9.56 (Mar 24) to 14.45, marking an increase of 4.89.
- For Return on Networth / Equity (%), as of Mar 25, the value is 19.07. This value is within the healthy range. It has increased from 13.39 (Mar 24) to 19.07, marking an increase of 5.68.
- For Return on Capital Employeed (%), as of Mar 25, the value is 21.29. This value is within the healthy range. It has increased from 17.64 (Mar 24) to 21.29, marking an increase of 3.65.
- For Return On Assets (%), as of Mar 25, the value is 11.23. This value is within the healthy range. It has increased from 7.97 (Mar 24) to 11.23, marking an increase of 3.26.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.10, marking an increase of 0.10.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.29. This value is within the healthy range. It has increased from 0.18 (Mar 24) to 0.29, marking an increase of 0.11.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.85. There is no change compared to the previous period (Mar 24) which recorded 0.85.
- For Current Ratio (X), as of Mar 25, the value is 1.87. This value is within the healthy range. It has increased from 1.58 (Mar 24) to 1.87, marking an increase of 0.29.
- For Quick Ratio (X), as of Mar 25, the value is 1.26. This value is within the healthy range. It has increased from 0.99 (Mar 24) to 1.26, marking an increase of 0.27.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.35. This value is within the healthy range. It has increased from 0.87 (Mar 24) to 4.35, marking an increase of 3.48.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 11.11. This value is below the healthy minimum of 20. It has increased from 9.50 (Mar 24) to 11.11, marking an increase of 1.61.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 8.19. This value is below the healthy minimum of 20. It has increased from 5.85 (Mar 24) to 8.19, marking an increase of 2.34.
- For Earning Retention Ratio (%), as of Mar 25, the value is 88.89. This value exceeds the healthy maximum of 70. It has decreased from 90.50 (Mar 24) to 88.89, marking a decrease of 1.61.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 91.81. This value exceeds the healthy maximum of 70. It has decreased from 94.15 (Mar 24) to 91.81, marking a decrease of 2.34.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 18.58. This value is within the healthy range. It has increased from 12.61 (Mar 24) to 18.58, marking an increase of 5.97.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 12.21. This value is within the healthy range. It has increased from 7.21 (Mar 24) to 12.21, marking an increase of 5.00.
- For Enterprise Value (Cr.), as of Mar 25, the value is 94,555.16. It has increased from 75,275.95 (Mar 24) to 94,555.16, marking an increase of 19,279.21.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.16. This value exceeds the healthy maximum of 3. It has increased from 3.76 (Mar 24) to 4.16, marking an increase of 0.40.
- For EV / EBITDA (X), as of Mar 25, the value is 17.26. This value exceeds the healthy maximum of 15. It has decreased from 19.15 (Mar 24) to 17.26, marking a decrease of 1.89.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.07. This value exceeds the healthy maximum of 3. It has increased from 3.68 (Mar 24) to 4.07, marking an increase of 0.39.
- For Retention Ratios (%), as of Mar 25, the value is 88.88. This value exceeds the healthy maximum of 70. It has decreased from 90.49 (Mar 24) to 88.88, marking a decrease of 1.61.
- For Price / BV (X), as of Mar 25, the value is 5.38. This value exceeds the healthy maximum of 3. It has increased from 5.16 (Mar 24) to 5.38, marking an increase of 0.22.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.07. This value exceeds the healthy maximum of 3. It has increased from 3.68 (Mar 24) to 4.07, marking an increase of 0.39.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.03, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Lupin Ltd:
- Net Profit Margin: 14.55%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 21.29% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 19.07% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 12.21
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.26
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 23.2 (Industry average Stock P/E: 52.86)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.29
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 14.55%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Kalpataru Inspire, 3rd Floor, Mumbai Maharashtra 400055 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mrs. Manju D Gupta | Chairperson |
| Mr. Nilesh D Gupta | Managing Director |
| Ms. Vinita Gupta | Director & CEO |
| Mr. Ramesh Swaminathan | Executive Director & Global CFO |
| Mr. Mark D McDade | Independent Director |
| Dr. Punita Kumar-Sinha | Independent Director |
| Mr. Jean-Luc Belingard | Independent Director |
| Mr. Jeffrey Kindler | Independent Director |
| Mr. Alfonso Zulueta | Independent Director |
| Mr. K B S Anand | Independent Director |
| Mr. Punita Lal | Independent Director |
FAQ
What is the intrinsic value of Lupin Ltd?
Lupin Ltd's intrinsic value (as of 16 January 2026) is ₹1653.09 which is 24.72% lower the current market price of ₹2,196.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,00,308 Cr. market cap, FY2025-2026 high/low of ₹2,228/1,774, reserves of ₹19,541 Cr, and liabilities of ₹33,500 Cr.
What is the Market Cap of Lupin Ltd?
The Market Cap of Lupin Ltd is 1,00,308 Cr..
What is the current Stock Price of Lupin Ltd as on 16 January 2026?
The current stock price of Lupin Ltd as on 16 January 2026 is ₹2,196.
What is the High / Low of Lupin Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Lupin Ltd stocks is ₹2,228/1,774.
What is the Stock P/E of Lupin Ltd?
The Stock P/E of Lupin Ltd is 23.2.
What is the Book Value of Lupin Ltd?
The Book Value of Lupin Ltd is 430.
What is the Dividend Yield of Lupin Ltd?
The Dividend Yield of Lupin Ltd is 0.55 %.
What is the ROCE of Lupin Ltd?
The ROCE of Lupin Ltd is 21.3 %.
What is the ROE of Lupin Ltd?
The ROE of Lupin Ltd is 20.6 %.
What is the Face Value of Lupin Ltd?
The Face Value of Lupin Ltd is 2.00.